Latest News and Press Releases

- NDC-0524 is a First-in-class Monoclonal Antibody with High Selectivity for Nitrated Alpha-synuclein (nSyn) and is Expected to Begin a Randomized Phase 1/2a Trial in the Fourth Quarter of 2025 -...

- Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated Alpha-synuclein, a Hallmark of Parkinson’s Disease (PD) -Company...

-Development Candidate NDC-0524 is a First-in-Class, Humanized Therapeutic Antibody with High Affinity and Selectivity for Nitrated -Synuclein, which is Rapidly Being Advanced into the Clinic for the...

-Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein-Advancing...

BRISBANE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...

BRISBANE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...

BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...

BRISBANE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...

BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...

-Data Elucidate Role of Company-identified Enzyme, Synuclein Nitrase, in Parkinson’s Disease- BRISBANE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical...